Related Experiment Videos
Boron neutron capture therapy for malignant gliomas
A Z Diaz1, J A Coderre, A D Chanana
1Medical Department, Brookhaven National Laboratory, Upton, NY 11973-5000, USA. azdiaz@bnl.gov
Annals of Medicine
|March 11, 2000
Summary
Boron neutron capture therapy (BNCT) uses boron-10 to target tumor cells with radiation. Achieving a high boron-10 concentration in tumors versus normal brain is key for effective glioblastoma treatment.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Boron neutron capture therapy (BNCT) offers targeted radiation for tumors.
- BNCT relies on boron-10's reaction with thermal neutrons to release cell-damaging particles.
- High linear energy transfer (LET) particles from the reaction exhibit high relative biological effectiveness (RBE).
Purpose of the Study:
- To evaluate the efficacy of BNCT for glioblastoma multiforme (GBM).
- To determine the critical factor for therapeutic gain in BNCT for GBM.
Main Methods:
- Utilizing the 10B(n,alpha)7Li reaction for targeted cell killing.
- Focusing on preferential accumulation of boron-10 in tumor cells over normal brain cells.
- Investigating the required boron-10 concentration and neutron fluence for therapeutic effect.
Main Results:
- The therapeutic gain of BNCT is primarily determined by the boron-10 concentration ratio between tumor and normal brain cells.
- Successful BNCT requires approximately 10(9) boron-10 atoms/cell in the tumor.
- An adequate thermal neutron fluence of approximately 10(12) neutrons/cm2 is necessary.
Conclusions:
- Preferential boron-10 accumulation in GBM cells is crucial for effective BNCT.
- BNCT holds promise for selective radiation dose delivery to tumor tissue.
- The ratio of boron-10 concentration in tumor to normal brain cells dictates the therapeutic outcome.